Expressions of CD133 and CD105 in lung cancer tissue and their clinical significance

Objective:To investigate the expressions of tumor stem cell marker CD133 and tumor vascular endothelial cell marker CD105 in lung cancer tissue and their clinical significance.Methods:Streptavidin-biotin-peroxidase complex(SABC)-immunohistochemical staining was used to detect the expression of CD133 and CD105 in 65 cases of lung cancer tissue and 30 specimens of adjacent non-cancerous tissue.The relationship between the expression of CD133/CD105 and tumor size,histological types,differentiation,TNM stage,lymphoid metastasis,and prognosis were analyzed.Results:The positive expression rates of CD133 and CD105 in lung cancer tissues were significantly higher than those in adjacent non cancerous tissues,respectively(69.2% vs 26.7% and 67.7% vs 10.0%,both P0.05).The positive expression rates of CD133 and CD105 in the group with lymphoid metastasis were higher than those with non lymphoid metastasis,respectively(82.5% vs 48.0% and 80.0% vs 48.0%,both P0.05).The expressions of CD133 and CD105 were positively correlated with lymphoid metastasis with Pearson coefficient r of 0.35 and 0.32,respectively(P0.05).No significant correlation was found between the expression of CD133/CD105 and tumor size,histological types,differentiation degree as well as TNM stage(P0.05).The expression of CD133 was positively correlated with the expression of CD105 in lung cancer tissue with Pearson coefficient r of 0.37(P0.05).Postoperative median survival periods of CD133 and CD105-positive group were significantly shorter than the CD133 and CD105-negative groups(37 months vs 66 months,35 months vs 70 months,respectively,both P0.05).Conclusion:The expression of CD133 and CD105 was associated with lymphoid metastasis and prognosis in patients with lung cancer.Their overexpression implies poor prognosis of lung cancer patients.